Show simple item record

dc.contributor.author Gonen, Galit
dc.date.accessioned 2017-10-31T14:50:10Z
dc.date.available 2017-10-31T14:50:10Z
dc.date.issued 2017-10
dc.identifier.citation 12 WASH. J.L. TECH.& ARTS 253 (2017) en_US
dc.identifier.issn 2157-2534
dc.identifier.uri http://hdl.handle.net/1773.1/1738
dc.description Washington Journal of Law, Technology & Arts, Volume 12 , Issue 3, Symposium 2017 en_US
dc.description.abstract Research into new uses for known drugs should be encouraged because the “repurposing” of known drug molecules can be a highly effective route of innovation for pharmaceutical companies. Investment in the development of these products should be rewarded. However, incentives that are designed to reward innovation must be in line with the size and value of the innovation in order to maintain a sustainable balance between incentivizing research and developing and encouraging a competitive market. In the context of encouraging innovation of new uses for known drugs, factors that facilitate access to drug development and innovation should also be considered in addition to incentives. en_US
dc.language.iso en_US en_US
dc.publisher Seattle: Washington Journal of Law, Technology & Arts, University of Washington School of Law en_US
dc.subject Intellectual Property en_US
dc.subject Future of Innovation in Medicine Conference en_US
dc.title Innovation in Known Drugs – The European Angle en_US
dc.type Article en_US
dc.rights.holder Copyright Galit Gonen en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search digital.law


Advanced Search

Browse

My Account